2003
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2003, 172: 291-297. PMID: 14634716, DOI: 10.1007/s00213-003-1658-9.Peer-Reviewed Original ResearchConceptsFederal Drug AdministrationSide effectsDrinking daysAlcohol dependenceDouble-blind fashionEfficacy of naltrexoneAbnormal involuntary movementsComorbid alcohol dependenceHeavy drinking daysTreatment of alcoholismSymptoms of schizophreniaRelapse prevention strategiesNegative Symptom ScaleNaltrexone augmentationTime-line follow-back methodNeuroleptic medicationNeuroleptic treatmentEffective medicationsMedication complianceComorbid schizophreniaOutpatient studyWeekly therapyEffective pharmacotherapyConclusionsThese dataInvoluntary movements
2001
Quantitative Morphology of the Caudate and Putamen in Patients With Cocaine Dependence
Jacobsen LK, Giedd JN, Gottschalk C, Kosten TR, Krystal JH. Quantitative Morphology of the Caudate and Putamen in Patients With Cocaine Dependence. American Journal Of Psychiatry 2001, 158: 486-489. PMID: 11229995, DOI: 10.1176/appi.ajp.158.3.486.Peer-Reviewed Original ResearchConceptsCocaine dependenceDopaminergic functionStriatal dopaminergic depletionTypical neuroleptic treatmentTotal brain volumeChronic cocaine dependenceCocaine-dependent subjectsChronic cocaine useStriatal hypertrophyExtrapyramidal symptomsNeuroleptic treatmentDopaminergic depletionHealthy subjectsBrain volumePutamen volumeCocaine useStriatal structuresCaudatePatientsPutamenHypertrophyMagnetic resonanceDeficitsQuantitative morphologySubjects
1998
Naltrexone Augmentation of Neuroleptics in Schizophrenia
Sernyak M, Glazer W, Heninger G, Charney D, Woods S, Petrakis I, Krystal J, Price L. Naltrexone Augmentation of Neuroleptics in Schizophrenia. Journal Of Clinical Psychopharmacology 1998, 18: 248-251.. PMID: 9617985, DOI: 10.1097/00004714-199806000-00011.Peer-Reviewed Original ResearchConceptsBrief Psychiatric Rating ScaleTotal BPRS scoreBPRS scoresNegative symptomsAddition of naltrexoneBPRS subscale scoresOngoing neuroleptic treatmentSingle-blind basisPlacebo-controlled trialSingle-blind fashionSubscale scoresBPRS total scorePsychiatric Rating ScaleDSM-III criteriaSubsequent treatmentRepeated-measures analysisNaltrexone augmentationNeuroleptic medicinesNeuroleptic regimenTransient exacerbationPlacebo armNeuroleptic treatmentClinical benefitRepeated-measures ANOVANaltrexone